About Gasdermin-D
Gasdermin-D (GSDMD) is a protein
from Homo sapiens identified by UniProt accession
P57764, 484 residues long.
MolForge cross-references it against 0 known binders and
485 disease associations.
Target properties
| Protein name | Gasdermin-D |
| UniProt accession | P57764 |
| Gene | GSDMD |
| Organism | Homo sapiens |
| Length | 484 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (485)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.34
- serum alanine aminotransferase measurement · score 0.28
- Oral ulcer · score 0.24
- aspartate aminotransferase measurement · score 0.24
- ulcer disease · score 0.23
- monocyte count · score 0.21
- neutrophil count · score 0.18
- leukocyte count · score 0.17
- myeloid white cell count · score 0.16
- neoplasm · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P57764-F1 | alphafold | PREDICTED | 77.85 | — |
Amino-acid sequence (484 residues)
MGSAFERVVR RVVQELDHGG EFIPVTSLQS STGFQPYCLV VRKPSSSWFW KPRYKCVNLS IKDILEPDAA EPDVQRGRSF HFYDAMDGQI QGSVELAAPG QAKIAGGAAV SDSSSTSMNV YSLSVDPNTW QTLLHERHLR QPEHKVLQQL RSRGDNVYVV TEVLQTQKEV EVTRTHKREG SGRFSLPGAT CLQGEGQGHL SQKKTVTIPS GSTLAFRVAQ LVIDSDLDVL LFPDKKQRTF QPPATGHKRS TSEGAWPQLP SGLSMMRCLH NFLTDGVPAE GAFTEDFQGL RAEVETISKE LELLDRELCQ LLLEGLEGVL RDQLALRALE EALEQGQSLG PVEPLDGPAG AVLECLVLSS GMLVPELAIP VVYLLGALTM LSETQHKLLA EALESQTLLG PLELVGSLLE QSAPWQERST MSLPPGLLGN SWGEGAPAWV LLDECGLELG EDTPHVCWEP QAQGRMCALY ASLALLSGLS QEPH
Explore Gasdermin-D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets